Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Correction: Dual role for miR-34a in the control of early progenitor proliferation and commitment in the mammary gland and in breast cancer.

Bonetti P, Climent M, Panebianco F, Tordonato C, Santoro A, Marzi MJ, Pelicci PG, Ventura A, Nicassio F.

Oncogene. 2019 Nov 8. doi: 10.1038/s41388-019-1094-x. [Epub ahead of print]

PMID:
31705063
2.

Dual role for miR-34a in the control of early progenitor proliferation and commitment in the mammary gland and in breast cancer.

Bonetti P, Climent M, Panebianco F, Tordonato C, Santoro A, Marzi MJ, Pelicci PG, Ventura A, Nicassio F.

Oncogene. 2019 Jan;38(3):360-374. doi: 10.1038/s41388-018-0445-3. Epub 2018 Aug 9. Erratum in: Oncogene. 2019 Nov 8;:.

3.

Author Correction: Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients.

Ni Q, Stevic I, Pan C, Müller V, Oliveira-Ferrer L, Pantel K, Schwarzenbach H.

Sci Rep. 2019 Dec 5;9(1):18700. doi: 10.1038/s41598-019-44070-0.

4.

Correction: miR-29a contributes to breast cancer cells epithelial-mesenchymal transition, migration, and invasion via downregulating histone H4K20 trimethylation through directly targeting SUV420H2.

Wu Y, Shi W, Tang T, Wang Y, Yin X, Chen Y, Zhang Y, Xing Y, Shen Y, Xia T, Guo C, Pan Y, Jin L.

Cell Death Dis. 2019 Nov 12;10(11):856. doi: 10.1038/s41419-019-2096-x.

5.

Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis.

Bianchi E, Ruberti S, Rontauroli S, Guglielmelli P, Salati S, Rossi C, Zini R, Tagliafico E, Vannucchi AM, Manfredini R.

Int J Mol Sci. 2017 Jan 13;18(1). pii: E145. doi: 10.3390/ijms18010145.

6.

MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1.

Li L, Yuan L, Luo J, Gao J, Guo J, Xie X.

Clin Exp Med. 2013 May;13(2):109-17. doi: 10.1007/s10238-012-0186-5. Epub 2012 May 24.

PMID:
22623155
7.

MiR-34a Inhibits Breast Cancer Proliferation and Progression by Targeting Wnt1 in Wnt/β-Catenin Signaling Pathway.

Si W, Li Y, Shao H, Hu R, Wang W, Zhang K, Yang Q.

Am J Med Sci. 2016 Aug;352(2):191-9. doi: 10.1016/j.amjms.2016.05.002. Epub 2016 May 7.

PMID:
27524218
8.

MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line.

Zhao G, Guo J, Li D, Jia C, Yin W, Sun R, Lv Z, Cong X.

DNA Cell Biol. 2013 Dec;32(12):699-707. doi: 10.1089/dna.2013.2130. Epub 2013 Sep 19.

9.

p53 Ser15 phosphorylation and histone modifications contribute to IR-induced miR-34a transcription in mammary epithelial cells.

Wang B, Li D, Kovalchuk O.

Cell Cycle. 2013 Jul 1;12(13):2073-83. doi: 10.4161/cc.25135. Epub 2013 Jun 6.

10.
11.

Delivery of biologically active miR-34a in normal and cancer mammary epithelial cells by synthetic nanoparticles.

Panebianco F, Climent M, Malvindi MA, Pompa PP, Bonetti P, Nicassio F.

Nanomedicine. 2019 Jul;19:95-105. doi: 10.1016/j.nano.2019.03.013. Epub 2019 Apr 25.

12.

MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis.

Hui C, Yujie F, Lijia Y, Long Y, Hongxia X, Yong Z, Jundong Z, Qianyong Z, Mantian M.

Breast Cancer Res. 2012 May 22;14(3):R80.

13.

miR-34a expression in human breast cancer is associated with drug resistance.

Li ZH, Weng X, Xiong QY, Tu JH, Xiao A, Qiu W, Gong Y, Hu EW, Huang S, Cao YL.

Oncotarget. 2017 Nov 6;8(63):106270-106282. doi: 10.18632/oncotarget.22286. eCollection 2017 Dec 5.

14.

MicroRNA-34a suppresses breast cancer cell proliferation and invasion by targeting Notch1.

Rui X, Zhao H, Xiao X, Wang L, Mo L, Yao Y.

Exp Ther Med. 2018 Dec;16(6):4387-4392. doi: 10.3892/etm.2018.6744. Epub 2018 Sep 17.

15.

MicroRNAs in the development and neoplasia of the mammary gland.

Jena MK.

Version 2. F1000Res. 2017 Jun 28 [revised 2017 Jan 1];6:1018. doi: 10.12688/f1000research.12005.2. eCollection 2017. Review.

16.

MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1.

Li XJ, Ji MH, Zhong SL, Zha QB, Xu JJ, Zhao JH, Tang JH.

Arch Med Res. 2012 Oct;43(7):514-21. doi: 10.1016/j.arcmed.2012.09.007. Epub 2012 Oct 16.

PMID:
23085450
17.

Author Correction: TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression.

Ottaviani S, Stebbing J, Frampton AE, Zagorac S, Krell J, de Giorgio A, Trabulo SM, Nguyen VTM, Magnani L, Feng H, Giovannetti E, Funel N, Gress TM, Jiao LR, Lombardo Y, Lemoine NR, Heeschen C, Castellano L.

Nat Commun. 2019 Aug 14;10(1):3738. doi: 10.1038/s41467-019-11752-2.

18.

Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.

Bayraktar R, Ivan C, Bayraktar E, Kanlikilicer P, Kabil NN, Kahraman N, Mokhlis HA, Karakas D, Rodriguez-Aguayo C, Arslan A, Sheng J, Wong S, Lopez-Berestein G, Calin GA, Ozpolat B.

Clin Cancer Res. 2018 Sep 1;24(17):4225-4241. doi: 10.1158/1078-0432.CCR-17-1959. Epub 2018 May 10.

19.

Correction: Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer.

Zhao L, Wang W, Xu L, Yi T, Zhao X, Wei Y, Vermeulen L, Goel A, Zhou S, Wang X.

Oncogene. 2019 Nov;38(47):7279-7280. doi: 10.1038/s41388-019-0896-1.

PMID:
31481747
20.

Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma.

Giallongo C, Tibullo D, Camiolo G, Parrinello NL, Romano A, Puglisi F, Barbato A, Conticello C, Lupo G, Anfuso CD, Lazzarino G, Volti GL, Palumbo GA, Di Raimono F.

Cell Death Dis. 2019 Oct 28;10(11):820. doi: 10.1038/s41419-019-2059-2.

Supplemental Content

Support Center